MAGE-6 Encodes HLA-DRβ1*0401-presented Epitopes Recognized by CD4+ T Cells from Patients with Melanoma or Renal Cell Carcinoma

摘要: CD4+ T cells modulate the magnitude and durability of CTL responses in vivo may serve as potent effector within tumor microenvironment. The current study was undertaken to define novel epitopes from broadly expressed antigen MAGE-6 that are recognized by cells. We have combined use a HLA-DR4/peptide binding algorithm with IFN-gamma enzyme-linked immunospot assay identify four nonoverlapping sequences derived protein served T-cell HLA-DR4+ donors. Strikingly, patients active melanoma or renal cell carcinoma failed secrete response MAGE-6-derived epitopes, whereas both normal donors cancer no evidence disease were responsive, particularly after short-term vitro stimulations peptide-pulsed dendritic Importantly, peptide-specific also HLA-DRbeta1*0401+ constitutively autologous transfected cDNA-elicited reacted against individual peptide vitro. These data suggest could useful vaccine candidate components provide an immune-monitoring index clinically important Th1-type immunity melanoma.